Certara Products Archives

博客

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

An IVIVC (in vitro-in vivo correlation) is a mathematical relationship that predicts key pharmacokinetic parameters…

Venkateswari Muthukrishnan2016 年 2 月 9 日

Blog

Back to the Future (of Pharmacometrics) with Dr. Lawrence Lesko

Pharmacometrics uses mathematical models of biology, pharmacology, disease, and physiology to describe and quantify interactions…

Suzanne Minton2015 年 12 月 1 日

Publication

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Bioavailability of orally administered drugs can be influenced by a number of factors including release…

webdev2015 年 11 月 1 日

Announcement

Introducing OpenCDISC Enterprise 3.0

Pinnacle 21 is proud to announce the launch of OpenCDISC Enterprise 3.0, which will be…

Simona Colucci2015 年 10 月 27 日

Blog

关于计算机系统验证的常见误解

Drug development professionals frequently use computer systems to help them understand the pharmacokinetics (PK) and…

Debra Fontana2015 年 1 月 28 日

Blog

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

As a scientist at Certara and proud Dad to my three kids, pediatric drug development…

Martin Beliveau2015 年 1 月 15 日

Publication

Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics

In drug development, considerable efforts are made to extrapolate from in vitro and preclinical findings…

webdev2014 年 10 月 1 日

Publication

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

Typically, pharmacokinetic-pharmacodynamic (PK/PD) models use plasma concentration as the input that drives the PD model. However, interindividual variability in…

webdev2014 年 7 月 9 日

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin…

webdev2013 年 9 月 1 日

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo.…

webdev2013 年 9 月 1 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Certara 产品

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

Back to the Future (of Pharmacometrics) with Dr. Lawrence Lesko

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Introducing OpenCDISC Enterprise 3.0

关于计算机系统验证的常见误解

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

订阅时事通讯

快捷链接

解决方案

联系我们